iBio - IBIO Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for iBio in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" IBIO shares.
View IBIO analyst ratings or view top-rated stocks.

2 Wall Street analysts have issued 1-year target prices for iBio's shares. Their IBIO share price forecasts range from $1.50 to $1.50. On average, they anticipate the company's stock price to reach $1.50 in the next twelve months. This suggests a possible upside of 855.4% from the stock's current price.
View analysts price targets for IBIO or view top-rated stocks among Wall Street analysts.

iBio's stock was trading at $0.4786 at the beginning of 2022. Since then, IBIO stock has decreased by 67.2% and is now trading at $0.1570.
View the best growth stocks for 2022 here.

iBio saw a decrease in short interest in the month of September. As of September 15th, there was short interest totaling 9,660,000 shares, a decrease of 9.1% from the August 31st total of 10,630,000 shares. Based on an average daily volume of 2,090,000 shares, the days-to-cover ratio is currently 4.6 days. Approximately 4.5% of the company's shares are short sold.
View iBio's Short Interest.

iBio, Inc. (NYSEAMERICAN:IBIO) released its earnings results on Monday, November, 15th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.01. The biotechnology company earned $0.21 million during the quarter. iBio had a negative net margin of 1,177.85% and a negative trailing twelve-month return on equity of 45.72%.

Shares of iBio reverse split on Tuesday, October 11th 2022. The 1-25 reverse split was announced on Tuesday, October 11th 2022. The number of shares owned by shareholders will be adjusted after the closing bell on Tuesday, October 11th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other iBio investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Heat Biologics (HTBX), Novavax (NVAX), Dynavax Technologies (DVAX), Co-Diagnostics (CODX), Nokia Oyj (NOK) and Moderna (MRNA).

iBio trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "IBIO."

Shares of IBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IBIO stock can currently be purchased for approximately $0.16.

iBio (NYSEAMERICAN:IBIO) has a market capitalization of $34.25 million and generates $2.37 million in revenue each year. The biotechnology company earns $-23,210,000.00 in net income (profit) each year or ($0.15) on an earnings per share basis.

iBio's mailing address is 600 Madison Ave Ste 1601, NEW YORK, NY 10022-1737, United States. The official website for the company is www.ibioinc.com. The biotechnology company can be reached via phone at (302) 355-0650, via email at ir@ibioinc.com, or via fax at 302-356-1173.